Gregory J. Flesher has recently filed a Form 3, indicating his ownership status as the Chief Operating Officer of Processa Pharmaceuticals, Inc. This filing is significant as it reflects his position and ownership in the company, which is important for stakeholders and market observers.

Background

Processa Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, specifically classified under SIC code 2834. The company is incorporated in Delaware and has its business address in Vero Beach, Florida. The recent filing was made on November 16, 2026, and is part of a series of filings that include Form 4 submissions dating back to 2021.

What the Filing Says

The Form 3 filing states that Gregory J. Flesher is an officer of Processa Pharmaceuticals and confirms that he owns one share of the company. This ownership update is crucial for transparency regarding executive holdings.

Impact

This filing may affect shareholders and potential investors in Processa Pharmaceuticals, as it provides insight into the ownership structure and executive involvement. It also highlights the importance of executive roles in the pharmaceutical industry.

What's Next

The filing does not say what happens next.

Ownership Details

According to the Form 3 filing, Gregory J. Flesher is the Chief Operating Officer of Processa Pharmaceuticals, Inc. and holds one share of the company's stock. This indicates a minimal personal investment relative to the company's overall equity structure.

Company Information

Processa Pharmaceuticals, Inc. is categorized under the SIC code 2834, which pertains to pharmaceutical preparations. The company is incorporated in Delaware and operates out of Vero Beach, Florida. The business address is listed as 601 21st Street, Suite 300, Vero Beach, FL 32960.

Filing Context

This Form 3 filing was made as of November 4, 2026, and officially filed on November 16, 2026. The filing is part of a broader set of disclosures, including previous Form 4 filings dating back to 2021, which provide ongoing updates about executive ownership changes.

Additional Information

The filing does not provide any information about future plans or potential changes in ownership or executive roles within Processa Pharmaceuticals, Inc. Furthermore, it does not include details on the company's financial performance or strategic initiatives that may influence stock ownership or executive compensation.